J and J ends trial of potential HIV vaccine
Johnson and Johnson halted mid stage testing of a potential HIV vaccine after results showed 25 percent protection in a study of about 2600 women at high risk in sub Saharan Africa. A separate late stage trial in men and transgender people continues in Europe and the Americas.